Drug intelligence / Profile preview

NG101m

Development stage: Phase 2
Lead developer: NeuGATE Theranostics
Modality: Small Molecules
Administration: Oral

Overview

NG101m is an oral small molecule drug developed by NeuGATE Theranostics as an adjuvant therapy for glioblastoma multiforme (GBM). It is administered in capsule form alongside standard-of-care chemoradiotherapy (temozolomide and radiation) in newly diagnosed GBM patients. The precise mechanism of action has not been defined or disclosed publicly. As of the latest updates, the drug is in Phase 1/2 clinical development for glioblastoma multiforme[1][3][4]. There are no reports of orphan drug status or approval to date.

Beyond the preview

Go deeper on NG101m.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NG101m.

Explore the full profile